Class & Mechanism — Local corpus: silent.
Research-documented benefits — Local corpus: silent.
General-knowledge benefits — Cagrilintide is a long-acting GLP-1 receptor agonist that is under investigation for the treatment of type 2 diabetes. It is designed to have a prolonged duration of action, allowing for less frequent dosing. [48]
Typical injectable protocol — Local corpus: silent.
Key risks / contraindications — Local corpus: silent.
Bottom line — Cagrilintide is an investigational GLP-1 receptor agonist for type 2 diabetes, with potential benefits in glycemic control and convenience due to its long-acting nature.
References
- Antimicrobial Peptides and Human Disease
- Basal Insulin Glargine 100 U_mL Versus 300 U_mL in Type 2 Diabetes
- GLP-1 and the kidney_ from physiology to pharmacology and outcomes in diabetes
- Growth Hormone Secretagogues in Clinical Practice
- Handbook of Biologically Active Peptides
- Human trials exploring anti-aging medicines — Guarente, Leonard (author)
- Incretin-Based Therapies for Type 2 Diabetes
- Kosmetik für Ärzte und Apotheker
- Nutrition in Mental Health_ A Handbook
- Peptide Therapeutics_ Design and Development
- Peptides_ Chemistry and Biology, 2nd Edition
- Platelets
- Prodrugs_ Challenges and Rewards
- Super Agers An Evidence-Based Approach to Longevity — Eric Topol
- The AI Revolution in Medicine_ GPT-4 and Beyond
- The discovery and development of liraglutide and semaglutide
Continue your journey
Cagrilintide vs Semaglutide: A Comparative Analysis of GLP-1 Receptor AgonistsRetatrutide vs Cagrilintide: Exploring Their Potential in Metabolic DisordersCagriSema: Mechanism, Benefits & Research EvidenceHCG (human chorionic gonadotropin): Mechanism, Benefits & Research EvidenceBrenipatide: Mechanism, Benefits & Research EvidenceSelank: Mechanism, Benefits & Research Evidence